US FDA approves Pfizer’s RSV vaccine, Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com

In a late-stage study, Pfizer’s vaccine, to be sold under the brand name Abrysvo, was 67 per cent effective among those aged 60 and older with two or more symptoms of RSV, and 85.7 per cent against severe illness defined by three or more symptoms., In a late-stage study, Pfizer’s vaccine, to be sold under the brand name Abrysvo, was 67 per cent effective among those aged 60 and older with two or more symptoms of RSV, and 85.7 per cent against severe illness defined by three or more symptoms., , Read More